Cargando…

THU019 Osilodrostat As An Emergency Alternative For Hypercortisolism In A Patient With An Impaired Liver Function

Disclosure: M. Minasyan: None. A. Bogusławska: None. A. Gamrat: None. A. Hubalewska-Dydejczyk: None. A. Gilis-Januszewska: None. Osilodrostat as an emergency alternative for hypercortisolism in a patient with an impaired liver function. A case presents a 34 year old woman with an active Cushing Dise...

Descripción completa

Detalles Bibliográficos
Autores principales:	Minasyan, Mari, Bogusławska, Anna, Gamrat, Aleksandra, Hubalewska-Dydejczyk, Alicja, Gilis-Januszewska, Aleksandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Neuroendocrinology And Pituitary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554347/ http://dx.doi.org/10.1210/jendso/bvad114.1100

Ejemplares similares

THU099 The Challenging Management Of Silent Corticotroph PitNET—From Very Aggressive To Mild Course Of Disease During Long Follow Up
por: Bogusławska, Anna, et al.
Publicado: (2023)

THU064 Clinical, Radiological Characteristics And Response To Somatostatin Analogues Of Acromegaly Patients With Different Patterns Of Growth Hormone Response After Oral Glucose Load
por: Godlewska, Magdalena, et al.
Publicado: (2023)

Diverse Manifestation of Acromegaly With Suspicion of Ectopic GHRH Secretion. Report of Two Cases
por: Godlewska, Magdalena, et al.
Publicado: (2021)

One Fourth of Adult Patients With Acromegaly Have Tall Stature With Similar Frequency in Males And Females
por: Bogusławska, Anna, et al.
Publicado: (2021)

FRI111 Venous Thromboembolism In Cushing Syndrome - A Call For Standardized Anticoagulation Regimen In Hypercortisolism
por: Minasyan, Mari, et al.
Publicado: (2023)

FRI320 The Various Clinical Outcomes Of Giant Prolactinomas In Men
por: Gilis-Januszewska, Aleksandra, et al.
Publicado: (2023)

Intrasellar Cavernous Hemangioma, a Rare Condition Causing Both Radiological And Clinical Difficulties- a Case Report
por: Nowak, Andrzej Jerzy, et al.
Publicado: (2021)

Testing of Adrenal Axis Function in Patients With Combined Pituitary Hormone Deficiency Caused by PROP1 Mutation
por: Gilis-Januszewska, Aleksandra, et al.
Publicado: (2021)

Pituitary Stalk Lesions - Single Center Long Term Observation
por: Kluczynski, Lukasz, et al.
Publicado: (2021)

THU038 Osilodrostat Dosing In Cushing’s Disease: A Pooled Analysis Of The LINC Program
por: Newell-Price, John, et al.
Publicado: (2023)

THU015 Unilateral Adrenal Hyperplasia Causing ACTH-independent Hypercortisolism
por: Mogar, Nikita, et al.
Publicado: (2023)

PMON160 Improvements in Clinical Signs of Hypercortisolism and Quality of Life According to Urinary and Late-Night Salivary Cortisol Levels in Patients with Cushing's Disease Treated with Osilodrostat
por: Biller, Beverly M K, et al.
Publicado: (2022)

Osilodrostat Is an Effective and Well-Tolerated Treatment for Cushing’s Disease (CD): Results From a Phase III Study With an Upfront, Randomized, Double-Blind, Placebo-Controlled Phase (LINC 4)
por: Gadelha, Mônica, et al.
Publicado: (2021)

THU070 Randomized, Placebo-controlled Phase 3 Trial Protocol Assessing The Efficacy And Safety Of Octreotide Subcutaneous Depot (CAM2029) In Patients With Acromegaly
por: Ferone, Diego, et al.
Publicado: (2023)

THU032 Osilodrostat Is Effective And Well Tolerated In Patients Of Asian And Non-Asian Origin With Cushing's Disease: A Pooled Analysis From LINC 3 And LINC 4
por: Snyder, Peter J, et al.
Publicado: (2023)

THU041 Clinical Improvements In Patients With Cushing’s Disease Treated With Osilodrostat According To Urinary And Late-night Salivary Cortisol Levels: Pooled Analysis From LINC 3 And LINC 4
por: Biller, Beverly M K, et al.
Publicado: (2023)

ODP340 NOVEL THERAPY OSILODROSTAT AS AN OPTION FOR RECURRENT CUSHING'S DISEASE
por: Marin, Luis Madera, et al.
Publicado: (2022)

MON-300 AIP Gene Germline Mutations in Non-Selected Patients with Apparently Sporadic Pituitary Macrodenomas
por: Trofimiuk-Muldner, Malgorzata, et al.
Publicado: (2020)

SAT-265 An Asynchronous Double Growth Hormone Secreting Pituitary Adenoma as a Cause of Rapid Tumor Regrowth After Initially Successful Surgery
por: Trofimiuk-Muldner, Malgorzata, et al.
Publicado: (2020)

Individualized medical treatment options in Cushing disease
por: Gilis-Januszewska, Aleksandra, et al.
Publicado: (2022)

SUN-454 Rationale and Methods for a Phase II Trial Evaluating Osilodrostat in Pediatric Patients with Cushing's Disease
por: Savage, Martin, et al.
Publicado: (2019)

SAT-263 A Vicious Cycle of Hypercortisolism - Cyclical Cushing’s Syndrome
por: Force, Bahar Kapoor, et al.
Publicado: (2020)

SAT-470 A Case of Acromegaly with Concomitant Hypercortisolism Presenting with Diabetic Ketoacidosis
por: Gonzales, Irish Judy
Publicado: (2019)

Long-Term Control of Urinary Free Cortisol With Osilodrostat in Patients With Cushing’s Disease: Final Results From the LINC 2 Study
por: Fleseriu, Maria, et al.
Publicado: (2021)

LBMON177 Dosing And Titration Of Osilodrostat In A Real-world Cohort Of US Patients With Endogenous Cushing's Disease: Analysis Of The ILLUSTRATE Study
por: Ioachimescu, Adriana Gabriela, et al.
Publicado: (2022)

LBMON176 Management, Safety, And Efficacy Of Osilodrostat Treatment In US Patients With Non-pituitary Cushing's Syndrome: Results From The ILLUSTRATE Study
por: Auchus, Richard Joseph, et al.
Publicado: (2022)

THU025 Acromegaly And Central Hyperthyroidism
por: Akhtar, Ahmad, et al.
Publicado: (2023)

OR16-2 Osilodrostat Treatment in Cushing's Disease (CD): Results from a Phase III, Multicenter, Double-Blind, Randomized Withdrawal Study (LINC 3)
por: Biller, Beverly MK, et al.
Publicado: (2019)

SAT-443 Osilodrostat Has No Clinically Relevant Effect on the Pharmacokinetic (PK) Profile of a Monophasic Oral Contraceptive in Healthy Females Receiving Cortisol Replacement Therapy
por: Breitschaft, Astrid, et al.
Publicado: (2019)

PMON163 Effect of Osilodrostat on Androgens and Adrenal Hormones in Patients With Cushing's Disease: Long-Term Findings From the Phase III, Prospective LINC 3 Study
por: Fleseriu, Maria, et al.
Publicado: (2022)

Traumatic brain injuries induced pituitary dysfunction: a call for algorithms
por: Gilis-Januszewska, Aleksandra, et al.
Publicado: (2020)

Pregnancy, thyroid, and the potential use of selenium
por: Hubalewska-Dydejczyk, Alicja, et al.
Publicado: (2019)

THU029 Subcutaneous Self-injections Of Lanreotide Is a Good Alternative For Acromegalic Patients With Long COVID Treated With Anticoagulants
por: Rosa, Isabella Naves, et al.
Publicado: (2023)

THU096 When TSH Alone Is Not Enough
por: Awasty, Sanjana S, et al.
Publicado: (2023)

THU021 Mysterious Resolution Of Cushing’s Disease
por: Whiteman, Daniel R, et al.
Publicado: (2023)

PMON162 Osilodrostat Provides Sustained Clinical Benefits and Improves Health-Related Quality of Life in Patients with Cushing's Disease: Results from the Phase III LINC 4 Study
por: Feelders, Richard, et al.
Publicado: (2022)

THU022 A Case Of Delayed Diagnosis Of Acromegaly
por: Blanchard, Kayla, et al.
Publicado: (2023)

OR27-3 Long-Term Results from the Phase III LINC 4 Study: Osilodrostat Maintained Normal Mean Urinary Free Cortisol in Patients with Cushing's Disease, with a Favorable Safety Profile
por: Auchus, Richard J, et al.
Publicado: (2022)

THU017 Severe Hypercortisolemia- A Biological Time Bomb
por: Munasinghe, Uthpala, et al.
Publicado: (2023)

THU027 Challenges In The Management Of Extreme Hyperglycemia In An Acromegalic Patient
por: Sonbol, Mark, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ics868vup0ldohju144bo094v7